Payer partnerships have proven to be a great option for DTx companies, especially in the US. However, in past HealthXL meetings we have seen that at least 50% of the room did not understand the requirements from payers, hence it seems like the DTx industry still has a lot to learn about this route to market. Join other senior leaders in this informal conversation, where we will talk about:
What are payers’ requirements to partner up with a DTx company (e.g economic savings, scalability, treatment duration, clinical evidence, etc)? How do these change across the different types of payers (e.g public payers, private payers, self-insured employers/commercial payers)?
How to get in front of the right decision makers within a payer organization?